Who are Baloxavir Marboxil tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ten-days oseltamivir + baloxavir marboxil, Placebo to Baloxavir Marboxil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/baloxavir-marboxil-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Baloxavir Marboxil tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Baloxavir Marboxil tablets (Baloxavir Marboxil tablets) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cap-dependent endonuclease inhibitor. Area: Virology/Infectious Disease.

phase 3 Cap-dependent endonuclease inhibitor Influenza PA endonuclease Virology/Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Baloxavir Marboxil tablets (Baloxavir Marboxil tablets) — Jiaxing AnDiCon Biotech Co.,Ltd. Baloxavir marboxil inhibits the influenza virus endonuclease, blocking viral cap-dependent transcription and preventing viral replication.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Baloxavir Marboxil tablets TARGET	Baloxavir Marboxil tablets	Jiaxing AnDiCon Biotech Co.,Ltd	phase 3	Cap-dependent endonuclease inhibitor	Influenza PA endonuclease
Ten-days oseltamivir + baloxavir marboxil	Ten-days oseltamivir + baloxavir marboxil	UMC Utrecht	phase 3	Neuraminidase inhibitor and cap-dependent endonuclease inhibitor	Neuraminidase and cap-dependent endonuclease
Placebo to Baloxavir Marboxil	Placebo to Baloxavir Marboxil	Shionogi	phase 3	Cap-dependent endonuclease inhibitor	Influenza virus PA endonuclease (cap-dependent endonuclease)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cap-dependent endonuclease inhibitor class)

Jiaxing AnDiCon Biotech Co.,Ltd · 1 drug in this class
Shionogi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Baloxavir Marboxil tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/baloxavir-marboxil-tablets. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing